CASCADEplus

The CASCADEplus system explained.

It is a bit of a challenge to explain the basic principles of the CASCADEplus system. It is especially challenging to explain it to people that are not familiar with cancer research and related issues. The CASCADEplus system is a rather simple approach to a complex problem.

So let's get into some basic context?

Over the past decades a lot of academic cancer researchers have published a megaton of data, scientific papers and so on. Though in contrast to that fact, we're only seeing small steps in the area of new - FDA approved - anticancer medicines and meaningful impact making treatments. And second to that, when those new medicines get approved, they get often only approved for a single type of cancer. Such albeit a broader application, against other types of cancer, seems to be very plausible.

Now let's take a step back and imagine the following situation:

You have a frontdoor with five different locks on it and thus you need five different keys to open that door. On a saturday evening, you go out to the cinema and when you return, you notice that you've lost all the keys.

What to do now? A first and logic thought could be: ring a local locksmith! So accordingly the locksmith arrives, he evaluates the situation thoroughly, but he subsequently provides you with just a single key. He thereby claims that: there's a fair chance, that you can get into the house with just that single key.

You pay him $500 and the guy leaves. And yes, you'll try that single key on all locks. As expected: only one of the locks opens. So you have no solution, the door is still locked and you're left outside at freezing temperatures...

In the context of anti-cancer therapy, your oncologist is herein a kind of locksmith. He or she knows very well that there are five other locks that need to be opened. The amount of publications related to compelling anticancer targets is greater than the approval of such anticancer drugs. So seen from that perspective: it is a sad fact, often your oncologist can only apply one or two keys, as all the other possible keys, still lack a FDA approval or have not been thoroughly researched.

In the CASCADEplus system we simply search for a natural equivalent of already approved anti-cancer drugs and proven adjuvants. So if a dried berry from the Andes mountains or a capsulated fungus from southern Siberia, provides the same blocking effects against XYZ targets as FDA approved anticancer drugs, the particular natural substances can or may be incorporated into the CASCADEplus system.

The CASCADEplus system only incorporates natural substances, when scientific data has been made publicly via credible academic research papers. So the sources of information are not Facebook or Instagram. And yes, there's really a very substantial amout of credible scientific data available, regarding those dried berries from the Peruvian Andes, fungus from southern Siberia and not of a lesser importance: traditional herbal medicines from China. You may want to check some of those credible scientific references.

Another key feature - perhaps the most important feature - of the CASCADEplus anticancer system, is the fact that from day one, a broad variety of targets is either being blocked or stimulated. This is different compared to anticancer therapies that are applied in clinics and hospitals.

In 'traditional' anticancer therapies, they apply approved 'first option' therapies for specific varieties of cancer. And if those 'first option' therapy doesn't lead to the wished outcome, only than oncologists will or may start to think about other treatment strategies. So if immunotherapy is the first option - single target - for a particular type of cancer and the second option is anticancer drug that interferes with DNA translation, the CASCADEplus approach would be: start from day 1. with both immunotherapy and translation inteference.

So very factual stateted: all the herbs and supplements that are part of the CASCADEplus system are not aimed at a single target, but they rather aim dozens of (key) targets. Not only inside cancer cells, but also on the surface of cancer cells, dito on Natural Killer (NK) - and T-cells. This approach is uniue.